戈利木单抗治疗类风湿关节炎
Golimumab for Rheumatoid Arthritis.
作者信息
Pelechas Eleftherios, Voulgari Paraskevi V, Drosos Alexandros A
机构信息
Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece.
出版信息
J Clin Med. 2019 Mar 20;8(3):387. doi: 10.3390/jcm8030387.
Abstract
Since the advent of infliximab for the treatment of rheumatoid arthritis (RA), new genetically-engineered molecules have appeared. This review aims to present the current data and body of evidence for golimumab (GLM). Safety, efficacy, tolerability and immunogenicity are all being investigated, not only through phase III trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-MORE, GO-FURTHER, GO-NICE), but also through studies of real-world data. It seems that GLM in the subcutaneous form is an efficacious molecule with a good safety profile at the standard dosage scheme, but a 100 mg subcutaneous dose is associated with a higher risk of opportunistic infections, lymphoma and demyelination. Furthermore, when compared to other tumor necrosis factor-α molecules, it is non-inferior, and, at some points, such as when it comes to immunogenicity and persistence of the drug, it has a better profile. In summary, GLM is an effective, well-tolerated option for the treatment of RA, for both the clinician and patients who are seeking a convenient dosage scheme.
摘要
自从英夫利昔单抗用于治疗类风湿关节炎（RA）以来，出现了新的基因工程分子。本综述旨在介绍戈利木单抗（GLM）的当前数据和证据。不仅通过III期试验（GO-BEFORE、GO-FORWARD、GO-AFTER、GO-MORE、GO-FURTHER、GO-NICE），还通过真实世界数据研究，对安全性、有效性、耐受性和免疫原性进行了全面调查。皮下注射剂型的GLM似乎是一种有效的分子，在标准剂量方案下具有良好的安全性，但100mg皮下注射剂量与机会性感染、淋巴瘤和脱髓鞘的较高风险相关。此外，与其他肿瘤坏死因子-α分子相比，它并不逊色，并且在某些方面，如免疫原性和药物持久性方面，表现更佳。总之，对于寻求便捷给药方案的临床医生和患者而言，GLM是治疗RA的一种有效且耐受性良好的选择。
相似文献
1
Golimumab for Rheumatoid Arthritis.戈利木单抗治疗类风湿关节炎
J Clin Med. 2019 Mar 20;8(3):387. doi: 10.3390/jcm8030387.
2
Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.戈利木单抗：一种新型肿瘤坏死因子-α抑制剂的疗效和耐受性评价。
Clin Ther. 2010 Sep;32(10):1681-703. doi: 10.1016/j.clinthera.2010.09.003.
3
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.肿瘤坏死因子α抑制剂治疗后活动性类风湿关节炎患者使用戈利木单抗（GO-AFTER研究）：一项多中心、随机、双盲、安慰剂对照的III期试验
Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26.
4
Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.在真实临床条件下，戈利木单抗治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎患者的有效性和安全性：德国非干预性 GO-NICE 研究。
BMJ Open. 2018 Jun 14;8(6):e021082. doi: 10.1136/bmjopen-2017-021082.
5
Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.皮下注射戈利木单抗治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎的5项临床试验的5年安全性数据。
J Rheumatol. 2016 Dec;43(12):2120-2130. doi: 10.3899/jrheum.160420. Epub 2016 Nov 1.
6
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.戈利木单抗：用于治疗类风湿性关节炎、银屑病关节炎和强直性脊柱炎。
BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005.
7
Golimumab: A Review in Inflammatory Arthritis.戈利木单抗：治疗炎症性关节炎的研究进展。
BioDrugs. 2017 Jun;31(3):263-274. doi: 10.1007/s40259-017-0217-6.
8
A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.一项针对接受静脉注射戈利木单抗或英夫利昔单抗治疗的类风湿关节炎患者的输注时间和治疗满意度的真实世界、多中心观察性研究。
J Med Econ. 2018 Jul;21(7):724-731. doi: 10.1080/13696998.2018.1472098. Epub 2018 May 25.
9
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗的免疫原性及其在类风湿关节炎、银屑病关节炎和强直性脊柱炎患者中的临床相关性。
Rheumatology (Oxford). 2019 Mar 1;58(3):441-446. doi: 10.1093/rheumatology/key309.
10
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.静脉注射戈利木单抗联合甲氨蝶呤治疗 < 65 岁和 ≥ 65 岁类风湿关节炎患者的疗效和安全性。
Arthritis Res Ther. 2019 Aug 20;21(1):190. doi: 10.1186/s13075-019-1968-x.
引用本文的文献
1
Targeting rheumatoid arthritis: a molecular perspective on biologic therapies and clinical progress.靶向类风湿关节炎：生物疗法与临床进展的分子视角
J Biol Eng. 2025 Jul 24;19(1):67. doi: 10.1186/s13036-025-00534-8.
2
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.阿巴西普、戈利木单抗和托珠单抗作为当前治疗中具有不同作用机制的选定生物原研改善病情抗风湿药。
J Clin Med. 2025 Mar 19;14(6):2107. doi: 10.3390/jcm14062107.
3
Current Immunotherapy Strategies for Rheumatoid Arthritis: The Immunoengineering and Delivery Systems.类风湿关节炎的当前免疫治疗策略：免疫工程与递送系统
Research (Wash D C). 2023 Oct 17;6:0220. doi: 10.34133/research.0220. eCollection 2023.
4
The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.药物计量学在推进自身免疫性疾病治疗中的作用。
Pharmaceutics. 2024 Dec 5;16(12):1559. doi: 10.3390/pharmaceutics16121559.
5
Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review.靶向炎症的双相情感障碍单克隆抗体精准治疗：一项叙述性综述
Ther Adv Psychopharmacol. 2024 Feb 6;14:20451253241227772. doi: 10.1177/20451253241227772. eCollection 2024.
6
Network Pharmacology and Experimental Validation Explore the Pharmacological Mechanisms of Herb Pair for Treating Rheumatoid Arthritis.网络药理学与实验验证探索治疗类风湿关节炎的药对的药理机制。
Comb Chem High Throughput Screen. 2024;27(12):1808-1822. doi: 10.2174/0113862073263839231129163200.
7
Therapeutic Antibodies in Medicine.医学中的治疗性抗体。
Molecules. 2023 Sep 5;28(18):6438. doi: 10.3390/molecules28186438.
8
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments.将纳米技术与单克隆抗体药物相结合治疗类风湿性关节炎。
J Nanobiotechnology. 2023 Mar 25;21(1):105. doi: 10.1186/s12951-023-01857-8.
9
Discovery of a Non-competitive TNFR1 Antagonist Affibody with Picomolar Monovalent Potency That Does Not Affect TNFR2 Function.发现一种具有皮摩尔单价效力的非竞争性 TNFR1 拮抗剂亲和体，不会影响 TNFR2 功能。
Mol Pharm. 2023 Apr 3;20(4):1884-1897. doi: 10.1021/acs.molpharmaceut.2c00385. Epub 2023 Mar 10.
10
Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents.新型生物制剂或靶向药物治疗类风湿关节炎所致肝损伤的研究
J Inflamm Res. 2023 Feb 3;16:443-452. doi: 10.2147/JIR.S395137. eCollection 2023.
本文引用的文献
1
Etanercept biosimilar SB-4.依那西普生物类似药 SB-4。
Expert Opin Biol Ther. 2019 Mar;19(3):173-179. doi: 10.1080/14712598.2019.1566456. Epub 2019 Jan 11.
2
The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.在日常临床实践中，与其他肿瘤坏死因子-α抑制剂相比，戈利木单抗治疗类风湿关节炎、强直性脊柱炎和银屑病关节炎的持久性：来自接受生物改善病情抗风湿药物治疗的斯洛文尼亚全国纵向患者登记处-BioRx.si 的观察结果。
Clin Rheumatol. 2019 Feb;38(2):297-305. doi: 10.1007/s10067-018-4324-7. Epub 2018 Oct 15.
3
Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center.类风湿关节炎治疗中的未满足需求。一项观察性研究和来自单一大学中心的真实体验。
Semin Arthritis Rheum. 2019 Feb;48(4):597-602. doi: 10.1016/j.semarthrit.2018.06.003. Epub 2018 Jun 22.
4
Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.在真实临床条件下，戈利木单抗治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎患者的有效性和安全性：德国非干预性 GO-NICE 研究。
BMJ Open. 2018 Jun 14;8(6):e021082. doi: 10.1136/bmjopen-2017-021082.
5
ABP 501 for the treatment of rheumatoid arthritis.ABP501 治疗类风湿性关节炎。
Expert Opin Biol Ther. 2018 Mar;18(3):317-322. doi: 10.1080/14712598.2018.1430760. Epub 2018 Jan 24.
6
High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.高 3 年戈利木单抗在类风湿关节炎、强直性脊柱炎和银屑病关节炎患者中的生存情况：来自 328 例患者的真实世界数据。
Clin Exp Rheumatol. 2018 Mar-Apr;36(2):254-262. Epub 2017 Nov 9.
7
Pathogenetic insights from the treatment of rheumatoid arthritis.从类风湿关节炎治疗中获得的发病机制见解。
Lancet. 2017 Jun 10;389(10086):2328-2337. doi: 10.1016/S0140-6736(17)31472-1.
8
Golimumab: A Review in Inflammatory Arthritis.戈利木单抗：治疗炎症性关节炎的研究进展。
BioDrugs. 2017 Jun;31(3):263-274. doi: 10.1007/s40259-017-0217-6.
9
Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.戈利木单抗在免疫介导的风湿性疾病中的持续使用：对类风湿关节炎、轴性脊柱关节炎和银屑病关节炎真实世界证据的系统评价
Patient Prefer Adherence. 2017 Apr 7;11:719-729. doi: 10.2147/PPA.S128665. eCollection 2017.
10
Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.戈利木单抗治疗强直性脊柱炎患者的血清生物标志物及临床/MRI证据变化：随机、安慰剂对照的GO-RAISE研究结果
Arthritis Res Ther. 2016 Dec 28;18(1):304. doi: 10.1186/s13075-016-1200-1.
Zotero 插件